Connect
← Return to Nubeqa Monotherapy vs Dual Therapy with ADT
Discussion
Nubeqa Monotherapy vs Dual Therapy with ADT
Prostate Cancer | Last Active: Jun 30 2:37pm | Replies (18)Comment receiving replies
@northoftheborder
While there may be listed side effects for Darolutamide, I have heard from a couple of dozen people at least, that are on it, and have found no side effects at all. I have heard from a couple of people that had side effects, but it was after stopping and starting again. There were a couple of cases where people reduce the dosages of it, But the side effects they reported were from ADT, more likely, since they were on both.
If you were to attend an Ancan.Org Advance prostate cancer meeting you would hear them constantly telling people to switch to Darolutamide. Listen to one of the previous sessions and you can hear it. That’s because it works so well.
I didn’t bring it up, but fatigue is a commonly reported problem with Apalutamide, Not really a problem for most people with Darolutamide.
Replies to "@northoftheborder While there may be listed side effects for Darolutamide, I have heard from a couple..."
Connect
@jeffmarc I'm on Apalutamide and have no side effects beyond the normal ones from my ADT. That's the challenge with anecdotal evidence: the people you're hearing from aren't randomly selected.
The clinical claim for Darolutamide is that it has fewer cognitive side effects because of the blood-brain barrier thing, but that doesn't eliminate the risk of other types of side-effects (cardio, digestive, liver, etc).
Fortunately, severe side-effects are relatively uncommon with all the -lutamides, so most of us are dealing mainly with the ADT ones.
Darolutamide + ADT doesn't seem to increase the risk of brain fog v.s. ADT alone, while Apalutamide may raise the risk by a couple of percentage points, but brain fog from ADT still overshadows any from the ARSI. That's why there are studies underway to see if we can do without ADT and continue on just the ARSI.